Technical Analysis for GDTC - CytoMed Therapeutics Limited

Grade Last Price % Change Price Change
B 2.31 -4.36% -0.11
GDTC closed down 4.36 percent on Friday, November 1, 2024, on 12 percent of normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Wide Bands Range Expansion 0.00%
Crossed Above 20 DMA Bullish -4.36%
Calm After Storm Range Contraction -4.36%
Wide Bands Range Expansion -4.36%
Gapped Up Strength -4.36%
Fell Below 20 DMA Bearish 3.57%
MACD Bearish Signal Line Cross Bearish 3.57%
Boomer Buy Setup Bullish Swing Setup 3.57%
Calm After Storm Range Contraction 3.57%

   Recent Intraday Alerts

Alert Time
Fell Below 20 DMA about 22 hours ago
20 DMA Support 1 day ago
Down 5% 1 day ago
Down 3% 1 day ago
Down 2 % 1 day ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

CytoMed Therapeutics Limited Description

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore. CytoMed Therapeutics Limited operates as a subsidiary of Glorious Finance Ltd


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Immune System Immunotherapy Cancer Treatment Immunotherapies Virotherapy Chimeric Antigen Receptor T Cell Natural Killer Cell Lymphocytes T Cells Human Cancers Pre Clinical Biopharmaceutical

Is GDTC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.5
52 Week Low 1.2
Average Volume 12,452
200-Day Moving Average 2.12
50-Day Moving Average 1.86
20-Day Moving Average 2.31
10-Day Moving Average 2.53
Average True Range 0.28
RSI (14) 53.05
ADX 38.09
+DI 31.84
-DI 14.69
Chandelier Exit (Long, 3 ATRs) 2.72
Chandelier Exit (Short, 3 ATRs) 2.53
Upper Bollinger Bands 2.90
Lower Bollinger Band 1.72
Percent B (%b) 0.5
BandWidth 51.29
MACD Line 0.17
MACD Signal Line 0.21
MACD Histogram -0.0325
Fundamentals Value
Market Cap 26.58 Million
Num Shares 11.5 Million
EPS -0.28
Price-to-Earnings (P/E) Ratio -8.23
Price-to-Sales 50.45
Price-to-Book 2.64
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.56
Resistance 3 (R3) 2.58 2.52 2.52
Resistance 2 (R2) 2.52 2.45 2.51 2.51
Resistance 1 (R1) 2.41 2.41 2.38 2.39 2.49
Pivot Point 2.34 2.34 2.33 2.33 2.34
Support 1 (S1) 2.24 2.28 2.20 2.22 2.12
Support 2 (S2) 2.17 2.24 2.16 2.10
Support 3 (S3) 2.06 2.17 2.09
Support 4 (S4) 2.05